Sunday, February 19, 2017 3:04:19 PM
ACNH (T/$10)...Achillion Pharm..."We see two very clear pathways for significant value creation for investors," wrote Ladenburg analyst Christopher James in a note. "The first is with the ACH-4471 program for multiple rare diseases driven by disorders of the complement system. The second path is through its HCV program, which is partnered with Janssen Pharmaceuticals."
ACHN (T/$10)...Achillion Pharm...
ACHN (T/$10)...Achillion Pharm...
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
